TAK Takeda Pharmaceutical
Filed: 11 Mar 21, 6:07am
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of March 2021
Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information furnished on this form:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|TAKEDA PHARMACEUTICAL COMPANY LIMITED|
|Date: March 11, 2021||By:||/s/ Christopher O'Reilly|
Global Head of Investor Relations
Takeda to Host Growth and Emerging Markets Strategic Update Call
Osaka, JAPAN, March 11, 2021 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host its Growth and Emerging Markets Strategic Update Call from 6:30 a.m. to 8:15 a.m. on March 11, 2021, EST (8:30 p.m. to 10:15 p.m. on March 11, 2021, JST). The presentation is now available as attached. In the conference call, Takeda will showcase its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit.
A webcast of the conference call is available on the IR Events page at https://www.takeda.com/investors/ir-events/.
|Media Contacts:||Investor Relations:|
+81 (0) 3-3278-2095
Media outside Japan
+1 (617) 588-9013
+81 (0) 3-3278-2306